Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.145
+0.085 (2.78%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Arbutus Biopharma Revenue
In the year 2024, Arbutus Biopharma had annual revenue of $6.17M, down -65.98%. Arbutus Biopharma had revenue of $1.57M in the quarter ending December 31, 2024, a decrease of -26.62%.
Revenue (ttm)
$6.17M
Revenue Growth
-65.98%
P/S Ratio
94.75
Revenue / Employee
$140,250
Employees
44
Market Cap
603.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ABUS News
- 22 days ago - Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle - Market Watch
- 22 days ago - Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire
- 7 weeks ago - Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - GlobeNewsWire
- 2 months ago - Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. - Seeking Alpha
- 3 months ago - Arbutus Provides 2025 Corporate and Financial Update - GlobeNewsWire
- 3 months ago - Arbutus: Positive Imdusiran Data Leads To Phase 2B Development - Seeking Alpha
- 4 months ago - Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - Business Wire